Together, these results imply that near-haploid and diploid/near-diploid cells show differential requirements for RAD51B expression and sensitivity to G2/M checkpoint regulations, and that RAD51B may be a promising candidate for targeted therapy in this challenging subtype of leukemia. The gene discussed is RAD51B; the disease is leukemia.